Revolutionizing Oxidative Damage Treatment
- Oxidative damage has been linked to the etiology of a wide range of diseases including age related cardiovascular, eye and neurodegenerative diseases. It also plays a role in cancer and many genetic diseases. The initial targets for these small molecule drugs that induce cellular protection against oxidative damage are:
- 1) Retinitis pigmentosa, a genetic eye disease and age-related eye diseases such as macular degeneration and glaucoma.
- 2) Cardiovascular diseases with the goal of protecting the heart and other organs against ischemia/reperfusion damage, as occurs in heart attacks and stroke.
- 3) A gene therapy approach to increase the level of MSR enzymes in tissues is being developed, since recent findings have shown that specific methionine oxidation in proteins may play a role in disease pathogenesis.
- Lead compound and initial focus
- Prolindox has promising results using 3 drugs that protect cells against oxidative damage. One of the drugs is effective in slowing blindness in an animal model of the genetic disease, retinitis pigmentosa.
- Prolindox has obtained Orphan Drug Designation from the FDA for this lead compound to treat retinitis pigmentosa